CEACAM5 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "CEACAM5" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

7doi.org

2^nd place

4semanticscholar.org

11^th place

8^th place

1ensembl.org

1,626^th place

1,007^th place

1worldcat.org

5^th place

doi.org

Beauchemin N, Arabzadeh A (December 2013). "Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis". Cancer and Metastasis Reviews. 32 (3–4): 643–671. doi:10.1007/s10555-013-9444-6. PMID 23903773. S2CID 10344352.
Zhang X, Han X, Zuo P, Zhang X, Xu H (September 2020). "CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration". The Journal of International Medical Research. 48 (9): 300060520959478. doi:10.1177/0300060520959478. PMC 7536504. PMID 32993395.
Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP (April 1989). "Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule". Cell. 57 (2): 327–334. doi:10.1016/0092-8674(89)90970-7. PMID 2702691. S2CID 30740594.
Ilantzis C, DeMarte L, Screaton RA, Stanners CP (2002). "Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation". Neoplasia. 4 (2): 151–163. doi:10.1038/sj.neo.7900201. PMC 1550325. PMID 11896570.
Gisina A, Novikova S, Kim Y, Sidorov D, Bykasov S, Volchenko N, et al. (2021-01-01). "CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells". Cancer Biomarkers. 32 (1): 85–98. doi:10.3233/CBM-203187. PMID 34092615. S2CID 235359543.
LaPointe N, Hertle N, Hsu SC, Kellis J, King N, Littrell J, et al. (2021-05-20). "Validation of an immunohistochemical assay, CEACAM5 IHC 769, under development for use with the antibody-drug conjugate tusamitamab ravtansine (SAR408701)". Journal of Clinical Oncology. 39 (15_suppl): e21030. doi:10.1200/JCO.2021.39.15_suppl.e21030. ISSN 0732-183X. S2CID 236398737.
Kim YJ, Li W, Zhelev DV, Mellors JW, Dimitrov DS, Baek DS (2023-02-27). "Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates". Frontiers in Oncology. 13: 1124039. doi:10.3389/fonc.2023.1124039. PMC 10010383. PMID 36923424.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000105388 – Ensembl, May 2017

nih.gov

pubmed.ncbi.nlm.nih.gov

Beauchemin N, Arabzadeh A (December 2013). "Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis". Cancer and Metastasis Reviews. 32 (3–4): 643–671. doi:10.1007/s10555-013-9444-6. PMID 23903773. S2CID 10344352.
Zhang X, Han X, Zuo P, Zhang X, Xu H (September 2020). "CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration". The Journal of International Medical Research. 48 (9): 300060520959478. doi:10.1177/0300060520959478. PMC 7536504. PMID 32993395.
Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP (April 1989). "Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule". Cell. 57 (2): 327–334. doi:10.1016/0092-8674(89)90970-7. PMID 2702691. S2CID 30740594.
Ilantzis C, DeMarte L, Screaton RA, Stanners CP (2002). "Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation". Neoplasia. 4 (2): 151–163. doi:10.1038/sj.neo.7900201. PMC 1550325. PMID 11896570.
Ordoñez C, Screaton RA, Ilantzis C, Stanners CP (July 2000). "Human carcinoembryonic antigen functions as a general inhibitor of anoikis". Cancer Research. 60 (13): 3419–3424. PMID 10910050.
Gisina A, Novikova S, Kim Y, Sidorov D, Bykasov S, Volchenko N, et al. (2021-01-01). "CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells". Cancer Biomarkers. 32 (1): 85–98. doi:10.3233/CBM-203187. PMID 34092615. S2CID 235359543.
Kim YJ, Li W, Zhelev DV, Mellors JW, Dimitrov DS, Baek DS (2023-02-27). "Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates". Frontiers in Oncology. 13: 1124039. doi:10.3389/fonc.2023.1124039. PMC 10010383. PMID 36923424.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5".
Zhang X, Han X, Zuo P, Zhang X, Xu H (September 2020). "CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration". The Journal of International Medical Research. 48 (9): 300060520959478. doi:10.1177/0300060520959478. PMC 7536504. PMID 32993395.
Ilantzis C, DeMarte L, Screaton RA, Stanners CP (2002). "Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation". Neoplasia. 4 (2): 151–163. doi:10.1038/sj.neo.7900201. PMC 1550325. PMID 11896570.
Kim YJ, Li W, Zhelev DV, Mellors JW, Dimitrov DS, Baek DS (2023-02-27). "Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates". Frontiers in Oncology. 13: 1124039. doi:10.3389/fonc.2023.1124039. PMC 10010383. PMID 36923424.

semanticscholar.org

api.semanticscholar.org

Beauchemin N, Arabzadeh A (December 2013). "Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis". Cancer and Metastasis Reviews. 32 (3–4): 643–671. doi:10.1007/s10555-013-9444-6. PMID 23903773. S2CID 10344352.
Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP (April 1989). "Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule". Cell. 57 (2): 327–334. doi:10.1016/0092-8674(89)90970-7. PMID 2702691. S2CID 30740594.
Gisina A, Novikova S, Kim Y, Sidorov D, Bykasov S, Volchenko N, et al. (2021-01-01). "CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells". Cancer Biomarkers. 32 (1): 85–98. doi:10.3233/CBM-203187. PMID 34092615. S2CID 235359543.
LaPointe N, Hertle N, Hsu SC, Kellis J, King N, Littrell J, et al. (2021-05-20). "Validation of an immunohistochemical assay, CEACAM5 IHC 769, under development for use with the antibody-drug conjugate tusamitamab ravtansine (SAR408701)". Journal of Clinical Oncology. 39 (15_suppl): e21030. doi:10.1200/JCO.2021.39.15_suppl.e21030. ISSN 0732-183X. S2CID 236398737.

worldcat.org

search.worldcat.org

LaPointe N, Hertle N, Hsu SC, Kellis J, King N, Littrell J, et al. (2021-05-20). "Validation of an immunohistochemical assay, CEACAM5 IHC 769, under development for use with the antibody-drug conjugate tusamitamab ravtansine (SAR408701)". Journal of Clinical Oncology. 39 (15_suppl): e21030. doi:10.1200/JCO.2021.39.15_suppl.e21030. ISSN 0732-183X. S2CID 236398737.